Investigators at Forest Laboratories ($FRX) and Pierre Fabre Medicament say they're on track to file an NDA for the anti-depression drug levomilnacipran after racking up a fresh set of positive Phase III data. The study was the second of three late-stage clinical trials of the drug. "We have successfully completed two positive Phase III studies for the treatment of MDD in adults and plan to file a new drug application for levomilnacipran with the FDA later this year," said Dr. Marco Taglietti, the head of R&D at the Forest Research Institute. The application is slated for later this year with another Phase III readout expected soon. Release